Pulmonary hypertension (PH) is a frequent complication of interstitial lung diseases (ILD) that worsens morbidity and mortality. Cigarette smoking has a detrimental effect on transplant-free survival of patients with ILD, including patients with idiopathic pulmonary fibrosis (IPF).
Iron deficiency aggravates hypoxic pulmonary vasoconstriction, exacerbating the increase of pulmonary arterial pressure at high altitude (HA). This may be especially relevant for patients with pulmonary hypertension (PH) travelling to HA, who moreover have a high prevalence of iron deficiency.
Pulmonary arterial hypertension (PAH) is a disease of abnormal pulmonary vascular remodeling and vascular obliteration that results in right heart failure and death. PAH pathogenesis is strongly associated with mutations of the Transforming Growth Factor Beta (TGF-β) superfamily signaling pathway, which has previously been challenging to target therapeutically.
Pulmonary hypertension (PH) is a chronic and devastating disease that currently lacks effective therapies, often ultimately requiring lung transplantation. Pulmonary vascular cells are subjected to various mechanical forces, which contribute to cardiovascular remodeling in PH.
Selection of therapy for pulmonary arterial hypertension (PAH) requires tradeoffs among disease severity, therapeutic benefit, adverse effects, treatment burden, quality of life, and patient values. Although professional societies endorse shared decision-making (SDM) in this context, empirical data describing SDM in PAH are limited.
Pulmonary veno-occlusive disease (PVOD) is a rare and aggressive subtype of pulmonary arterial hypertension characterized by fibroproliferative obstruction of post-capillary pulmonary venules leading to increased pulmonary vascular resistance and progressive right ventricular failure.
Pulmonary arterial hypertension (PAH) is a rare, progressive disease with high morbidity and mortality. Real-world data from Israel are scarce. This study aimed to estimate the incidence, describe treatment patterns, and quantify healthcare utilization and costs associated with PAH in Israel.
Large bore mechanical thrombectomy (LBMT) is an effective therapy for intermediate-high risk PE, however, objective physiological endpoints to guide intraprocedural decision-making remain poorly defined.
